A Preliminary study of removal of some heavy metals from aqueous medium by a mesoporous hydroxysodalite zeolite prepared from basalt rich in calc-plagioclaseby alkali activation

This work presents an exploration of the use of hydroxysodalite zeolite prepared from basalt rich in calc-plagioclaseby alkali activation for removal of some heavy metals from aqueous medium. The preliminary results of batch and column experiments indicated a quantitative and fast removal of the three investigated ions, Cu2+, Pb2+ and Zn2+ from aqueous solutions. The data from the batch experiments and the column experiments jointly support the notion that hydroxysodalite zeolite prepared from basalt rich in calc-plagioclase is an efficient adsorbent for the investigated heavy metals.  Almost quantitative removal of the ions was achieved within a period of 15 min of exposure of the solution to the adsorbent in batch experiments and through passing a small column filled with the adsorbent. The highest removal efficiency  by the zeolite prepared from basalt rich in calc-plagioclase of  the three tested heavy metal Cu2+, Pb2+ and Zn2+ were 99.98% ,99.76% and 99.93 % respectively. Keywords: hydroxysodalite zeolite, basalt utilization, heavy ions removal, pollution  remediation DOI: 10.7176/CMR/12-7-09 Publication date:November 30th 2020

Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study

OBJECTIVES: Paediatric cancer is a leading cause of death for children. Children in low-income and middle-income countries (LMICs) were four times more likely to die than children in high-income countries (HICs). This study aimed to test the hypothesis that the COVID-19 pandemic had affected the delivery of healthcare services worldwide, and exacerbated the disparity in paediatric cancer outcomes between LMICs and HICs. DESIGN: A multicentre, international, collaborative cohort study. SETTING: 91 hospitals and cancer centres in 39 countries providing cancer treatment to paediatric patients between March and December 2020. PARTICIPANTS: Patients were included if they were under the age of 18 years, and newly diagnosed with or undergoing active cancer treatment for Acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, Wilms' tumour, sarcoma, retinoblastoma, gliomas, medulloblastomas or neuroblastomas, in keeping with the WHO Global Initiative for Childhood Cancer. MAIN OUTCOME MEASURE: All-cause mortality at 30 days and 90 days. RESULTS: 1660 patients were recruited. 219 children had changes to their treatment due to the pandemic. Patients in LMICs were primarily affected (n=182/219, 83.1%). Relative to patients with paediatric cancer in HICs, patients with paediatric cancer in LMICs had 12.1 (95% CI 2.93 to 50.3) and 7.9 (95% CI 3.2 to 19.7) times the odds of death at 30 days and 90 days, respectively, after presentation during the COVID-19 pandemic (p<0.001). After adjusting for confounders, patients with paediatric cancer in LMICs had 15.6 (95% CI 3.7 to 65.8) times the odds of death at 30 days (p<0.001). CONCLUSIONS: The COVID-19 pandemic has affected paediatric oncology service provision. It has disproportionately affected patients in LMICs, highlighting and compounding existing disparities in healthcare systems globally that need addressing urgently. However, many patients with paediatric cancer continued to receive their normal standard of care. This speaks to the adaptability and resilience of healthcare systems and healthcare workers globally

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality